AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20002951 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition Screening Tool (MST)
Number of subjects: 285
Study 20002951 — intervention group
Group type: COMPARATOR
Intervention: Subjective Global Assessment (SGA)
Number of subjects: 285
Study 17320729 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with LBP
Number of subjects: 29
Study 17320729 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (Control)
Number of subjects: 29
Study 15562267 — intervention group
Group type: EXPERIMENTAL
Intervention: Methionine load (100 mg/kg of body weight)
Number of subjects: 20
Study 15562267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11473657 — intervention group
Group type: EXPERIMENTAL
Intervention: NESP (0.45 microg/kg once weekly)
Number of subjects: 166
Study 11473657 — intervention group
Group type: COMPARATOR
Intervention: rHuEPO (50 U/kg twice weekly)
Number of subjects: 166
Study 9675959 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg/day)
Number of subjects: 98
Study 9675959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 8283892 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Number of subjects: 11
Study 8283892 — intervention group
Group type: COMPARATOR
Intervention: None (Control)
Number of subjects: 11
Study 2921077 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (2,160 mg/day)
Number of subjects: 27
Study 2921077 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-Ca group)
Number of subjects: 27
Study 31906754 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline
Number of subjects: 21
Study 31906754 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized Progesterone
Number of subjects: 21
Study 31906754 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 21
Study 29542251 — intervention group
Group type: EXPERIMENTAL
Intervention: Water aerobic exercise training (WAET)
Number of subjects: 26
Study 29542251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 26
Study 26684819 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-7 injections (3 weekly injections at weeks 8, 9, and 10)
Number of subjects: 29
Study 26684819 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-7 injections
Number of subjects: 29
Study 26684819 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-7 injections and dual ART intensification
Number of subjects: 29
Study 26684819 — intervention group
Group type: COMPARATOR
Intervention: Intensification alone
Number of subjects: 29
Study 24853636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Group
Number of subjects: 0
Study 24853636 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 22940889 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron(III)‐hydroxide sucrose complex, three doses of 100 mg/24 h during pre‐ and postoperative hospitalization and 1 pill/24 h of oral placebo
Number of subjects: 159
Study 22940889 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ferrous fumarate iron 1 pill/24 h pre‐ and postoperatively and during 1 month after discharge, and intravenous placebo while hospitalized
Number of subjects: 159
Study 22940889 — intervention group
Group type: COMPARATOR
Intervention: Oral and intravenous placebo pre‐ and postoperatively
Number of subjects: 159
Study 20208358 — intervention group
Group type: EXPERIMENTAL
Intervention: D-psicose (5 g)
Number of subjects: 26
Study 20208358 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 g)
Number of subjects: 26
Study 20208358 — intervention group
Group type: COMPARATOR
Intervention: D-glucose (5 g)
Number of subjects: 26
Study 18975521 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral verapamil 40 mg every 8 hours
Number of subjects: 40
Study 18975521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15754989 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy marijuana smokers after 24 hours of abstinence
Number of subjects: 0
Study 15754989 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy marijuana smokers after 28 days of abstinence
Number of subjects: 0
Study 15754989 — intervention group
Group type: COMPARATOR
Intervention: Healthy nonusing controls
Number of subjects: 0
Study 12007046 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation
Number of subjects: 0
Study 12007046 — intervention group
Group type: COMPARATOR
Intervention: Inpatient rehabilitation
Number of subjects: 0
Study 10397379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone and proguanil (1000 mg and 400 mg respectively, administered orally at 24-hour intervals for 3 doses)
Number of subjects: 163
Study 10397379 — intervention group
Group type: COMPARATOR
Intervention: Pyrimethamine/sulfadoxine (75 mg/1500 mg administered orally as a single dose)
Number of subjects: 163
Study 10397379 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone and proguanil
Number of subjects: 163
Study 10397379 — intervention group
Group type: COMPARATOR
Intervention: Pyrimethamine/sulfadoxine
Number of subjects: 163
Study 9251266 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal sensitivity in subjects with diabetes mellitus without retinopathy (1.17 +/- 0.29 gm/mm2)
Number of subjects: 105
Study 9251266 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal sensitivity in eyes with any type of retinopathy (1.94 +/- 1.33 gm/mm2)
Number of subjects: 105
Study 9251266 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal hypoesthesia as a test to detect diabetic retinopathy at a cut off value of 1.20 gm/mm2
Number of subjects: 105
Study 9251266 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal hypoesthesia for detecting presence of proliferative diabetic retinopathy at a cut off value of 1.49 gm/mm2
Number of subjects: 105
Study 1735830 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte transfusions
Number of subjects: 35
Study 1735830 — intervention group
Group type: COMPARATOR
Intervention: IVIG infusions
Number of subjects: 35
Study 6538844 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimoxatone, 40 mg oral dose
Number of subjects: 6
Study 6538844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 12225492 — intervention group
Group type: EXPERIMENTAL
Intervention: Bech-Rafaelsen Melancholia Scale (MES)
Number of subjects: 0
Study 12225492 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term and long-term treatment
Number of subjects: 0
Study 29486514 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE-083 (50-200 mg) administered unilaterally into rectus femoris (RF) or tibialis anterior (TA) muscles as 1 or 2 doses 3 weeks apart
Number of subjects: 58
Study 29486514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 27810310 — intervention group
Group type: EXPERIMENTAL
Intervention: LU+B420 (12g Litesse® Ultra polydextrose + 1010CFU Bifidobacterium animalisssp. lactis 420)
Number of subjects: 225
Study 27810310 — intervention group
Group type: EXPERIMENTAL
Intervention: B420 (1010CFU/d in microcrystalline cellulose, 12g/d)
Number of subjects: 225
Study 27810310 — intervention group
Group type: EXPERIMENTAL
Intervention: LU (12g/d)
Number of subjects: 225
Study 27810310 — intervention group
Group type: COMPARATOR
Intervention: Placebo (microcrystalline cellulose, 12g/d)
Number of subjects: 225
Study 27810310 — intervention group
Group type: EXPERIMENTAL
Intervention: B420 and LU+B420
Number of subjects: 225
Study 27810310 — intervention group
Group type: EXPERIMENTAL
Intervention: LU+B420
Number of subjects: 225
Study 25144827 — intervention group
Group type: EXPERIMENTAL
Intervention: Death as a primary endpoint
Number of subjects: 7986
Study 25144827 — intervention group
Group type: EXPERIMENTAL
Intervention: Death plus hospitalization as a primary endpoint
Number of subjects: 7986
Study 22209773 — intervention group
Group type: EXPERIMENTAL
Intervention: Nerve-sparing radical hysterectomy (NSRH)
Number of subjects: 25
Study 22209773 — intervention group
Group type: COMPARATOR
Intervention: Radical hysterectomy (RH)
Number of subjects: 25
Study 20040005 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus eluting coronary stent system (everolimus doses ranging from 53 to 181 microg)
Number of subjects: 0
Study 20040005 — intervention group
Group type: COMPARATOR
Intervention: Control not specified
Number of subjects: 0
Study 18784586 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary fixation using an interlocking nail without iliac bone graft
Number of subjects: 40
Study 18784586 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary fixation using an interlocking nail with iliac bone graft
Number of subjects: 40
Study 16150687 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Dissociative Checklist (CDC) administered to children with abuse histories
Number of subjects: 94
Study 16150687 — intervention group
Group type: COMPARATOR
Intervention: Child Dissociative Checklist (CDC) administered to children with ADHD
Number of subjects: 94
Study 16150687 — intervention group
Group type: COMPARATOR
Intervention: Child Dissociative Checklist (CDC) administered to control group (no abuse or psychiatric record)
Number of subjects: 94
Study 16150687 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis of CDC scores and duration of abusive experiences
Number of subjects: 94
Study 11961325 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAGNOdent laser evaluation
Number of subjects: 220
Study 11961325 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 220
Study 11961325 — intervention group
Group type: EXPERIMENTAL
Intervention: DIAGNOdent
Number of subjects: 220
Study 10027428 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiros Inhalation System (Dura Pharmaceuticals; 108 microg/actuation of albuterol sulfate equivalent to 90 microg of albuterol base)
Number of subjects: 283
Study 10027428 — intervention group
Group type: EXPERIMENTAL
Intervention: albuterol metered-dose inhaler (MDI; 90 microg/actuation of albuterol)
Number of subjects: 283
Study 10027428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 8622105 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin 15 mg/kg once daily (n = 15)
Number of subjects: 203
Study 8622105 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin 8 mg/kg once daily (n = 93)
Number of subjects: 203
Study 8622105 — intervention group
Group type: COMPARATOR
Intervention: Amikacin 7.5 mg/kg twice daily (n = 18)
Number of subjects: 203
Study 8622105 — intervention group
Group type: COMPARATOR
Intervention: Amikacin 7.5 mg/kg twice daily (n = 47)
Number of subjects: 203
Study 8622105 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin
Number of subjects: 203
Study 8622105 — intervention group
Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 203
Study 2045762 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER, 10 mg once daily for 2 weeks
Number of subjects: 28
Study 2045762 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ), 25 mg once daily for 2 weeks
Number of subjects: 28
Study 6168511 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic secretin
Number of subjects: 12
Study 6168511 — intervention group
Group type: COMPARATOR
Intervention: Natural secretin
Number of subjects: 12
Study 31910850 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 340
Study 31910850 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 340
Study 31117800 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious sedation with midazolam and fentanyl
Number of subjects: 5328
Study 31117800 — intervention group
Group type: COMPARATOR
Intervention: No sedation (Control)
Number of subjects: 5328
Study 28024090 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Pillars Practice Transformation Program
Number of subjects: 0
Study 28024090 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 0
Study 25158273 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin
Number of subjects: 142
Study 25158273 — intervention group
Group type: COMPARATOR
Intervention: Enuretic alarm
Number of subjects: 142
Study 23313581 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal vasopressin (AVP) 20 IU
Number of subjects: 2
Study 23313581 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 2
Study 22021025 — intervention group
Group type: EXPERIMENTAL
Intervention: VA MEDIC‐E intervention (pharmacist-led shared medical appointments program)
Number of subjects: 99
Study 22021025 — intervention group
Group type: COMPARATOR
Intervention: Standard primary care (control)
Number of subjects: 99
Study 19307466 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril/spironolactone (40 mg lisinopril/25 mg spironolactone)
Number of subjects: 18
Study 19307466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17589899 — intervention group
Group type: EXPERIMENTAL
Intervention: Body awareness therapy (2 hours weekly for 24 weeks)
Number of subjects: 21
Study 17589899 — intervention group
Group type: EXPERIMENTAL
Intervention: Body awareness therapy
Number of subjects: 21
Study 17589899 — intervention group
Group type: COMPARATOR
Intervention: Apparently healthy persons (control group)
Number of subjects: 21
Study 15217837 — intervention group
Group type: EXPERIMENTAL
Intervention: High AF1q expression (top tertile)
Number of subjects: 64
Study 15217837 — intervention group
Group type: COMPARATOR
Intervention: Low AF1q expression (lower 2 tertiles)
Number of subjects: 64
Study 15217837 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing AF1q expression level
Number of subjects: 64
Study 15217837 — intervention group
Group type: EXPERIMENTAL
Intervention: High AF1q expression
Number of subjects: 64
Study 11120401 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic interventions related to pharmacotherapy treatment adherence
Number of subjects: 0
Study 11120401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologic measures of medication adherence
Number of subjects: 0
Study 11120401 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment adherence interventions scale ratings
Number of subjects: 0
Study 9512836 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg daily)
Number of subjects: 3854
Study 9691876 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pressure ventilation via a laryngeal mask airway
Number of subjects: 40
Study 9691876 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous breathing via a laryngeal mask airway
Number of subjects: 40
Study 1926651 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (Monuril), 3-gram single dose
Number of subjects: 63
Study 1926651 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (Noroxine), 400 mg twice daily for 5 days
Number of subjects: 63
Study 1926651 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (Monuril)
Number of subjects: 63
Study 6310053 — intervention group
Group type: COMPARATOR
Intervention: Sotalol
Number of subjects: 24
Study 6310053 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 24
Study 6310053 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 24
Study 6310053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31956037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified platinum-based chemotherapy
Number of subjects: 248
Study 31956037 — intervention group
Group type: COMPARATOR
Intervention: Conventional anthracycline-based chemotherapy
Number of subjects: 248
Study 31291055 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial mild to moderate daily GER
Number of subjects: 0
Study 31291055 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent and aggravated GER
Number of subjects: 0
Study 31291055 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional depression
Number of subjects: 0
Study 31291055 — intervention group
Group type: EXPERIMENTAL
Intervention: GER new-onset rate
Number of subjects: 0
Study 31291055 — intervention group
Group type: EXPERIMENTAL
Intervention: GER disappearance rate
Number of subjects: 0
Study 31291055 — intervention group
Group type: EXPERIMENTAL
Intervention: GER prevalence
Number of subjects: 0
Study 31291055 — intervention group
Group type: EXPERIMENTAL
Intervention: GER persistence vs aggravation
Number of subjects: 0
Study 27718176 — intervention group
Group type: EXPERIMENTAL
Intervention: OAGB
Number of subjects: 201
Study 27718176 — intervention group
Group type: COMPARATOR
Intervention: LSG
Number of subjects: 201
Study 27078989 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenyi Capsule + Modified Yiqi Chutan Recipe (MYCR) + chemotherapy
Number of subjects: 80
Study 27078989 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 80
Study 27078989 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenyi Capsule + MYCR + chemotherapy
Number of subjects: 80
Study 24262291 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat overfeeding for 5 days
Number of subjects: 45
Study 24262291 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 45
Study 24262291 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-stimulation after high-fat overfeeding
Number of subjects: 45
Study 24262291 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat overfeeding
Number of subjects: 45
Study 22128078 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg subcutaneously every two weeks for 12 months
Number of subjects: 60
Study 22128078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21156950 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilatory strategy (tidal volumes of 6‐8 mL/kg, PEEP of 8‐10 cm H(2)O)
Number of subjects: 118
Study 21156950 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilatory strategy (tidal volumes of 10‐12 mL/kg, PEEP of 3‐5 cm H(2)O)
Number of subjects: 118
Study 21156950 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective ventilatory strategy
Number of subjects: 118
Study 21156950 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilatory strategy
Number of subjects: 118
Study 17627007 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun protection habits (varied by sex)
Number of subjects: 725
Study 17627007 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent class analysis (LCA)
Number of subjects: 725
Study 16330984 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin therapy for 6 weeks after negative venograms
Number of subjects: 1972
Study 16330984 — intervention group
Group type: COMPARATOR
Intervention: No further anticoagulation after negative venograms
Number of subjects: 1972
Study 16330984 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway including continuous epidural anesthesia
Number of subjects: 1972
Study 11996271 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous platelet concentrate (PC) reinfusion (9 to 20 U, 13.0 ± 5.4 U, 0.42 ± 0.22 U/kg) after open heart surgery.
Number of subjects: 16
Study 9080886 — intervention group
Group type: EXPERIMENTAL
Intervention: mefloquine
Number of subjects: 23
Study 9080886 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study 8442598 — intervention group
Group type: EXPERIMENTAL
Intervention: Active NCPAP (7.5 cm H2O)
Number of subjects: 8
Study 8442598 — intervention group
Group type: COMPARATOR
Intervention: Placebo NCPAP (< 1.5 cm H2O)
Number of subjects: 8
Study 3533272 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (maximum daily dose 18 mg)
Number of subjects: 12
Study 3533272 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (maximum daily dose 900 mg)
Number of subjects: 12
Study 30192751 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 112
Study 27460905 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 573
Study 27460905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol
Number of subjects: 573
Study 27460905 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 573
Study 24775575 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 units of onabotulinumtoxinA
Number of subjects: 28
Study 24775575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 22617934 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral position
Number of subjects: 20
Study 22617934 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 20
Study 22617934 — intervention group
Group type: EXPERIMENTAL
Intervention: Junior trainees
Number of subjects: 20
Study 22617934 — intervention group
Group type: EXPERIMENTAL
Intervention: Senior trainees
Number of subjects: 20
Study 20437555 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized stroke discharge orders
Number of subjects: 3361
Study 20437555 — intervention group
Group type: COMPARATOR
Intervention: Usual care (non-intervention hospitals)
Number of subjects: 3361
Study 18561584 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily azelaic acid 15% gel
Number of subjects: 72
Study 18561584 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily azelaic acid 15% gel
Number of subjects: 72
Study 15716474 — intervention group
Group type: EXPERIMENTAL
Intervention: Older subjects (ages 15-19)
Number of subjects: 0
Study 15716474 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger subjects (ages 8-14)
Number of subjects: 0
Study 12209299 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolene Hernia System (PHS)
Number of subjects: 206
Study 12209299 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein patch
Number of subjects: 206
Study 10685300 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone group (n = 30)
Number of subjects: 65
Study 10685300 — intervention group
Group type: COMPARATOR
Intervention: Standard group (n = 32)
Number of subjects: 65
Study 10685300 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal pneumocardiogram
Number of subjects: 65
Study 10685300 — intervention group
Group type: COMPARATOR
Intervention: Normal pneumocardiogram
Number of subjects: 65
Study 8685201 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine 37.5 mg/day
Number of subjects: 315
Study 8685201 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine 25 mg/day
Number of subjects: 315